Physician profile
Brian Ayuste
NPI 1104003458
$5,483.90
in general payments reported to CMS, 2019-2025
26 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $160 · 2021: $193 · 2022: $661 · 2023: $1,234 · 2024: $1,391 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,056 · Education: $49.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,055.75 |
| Education | $49.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $948.79 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $714.03 | 2024-2025 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $570.87 | 2019-2025 | Benlysta, Jesduvroq, Arexvy |
| Otsuka America Pharmaceutical, INC. | $498.07 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $395.30 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $325.41 | 2023-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.79 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $234.21 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.29 | 2021-2025 | |
| Vifor Pharma, INC. | $197.07 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $188.07 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $185.21 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $169.15 | 2020-2024 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $133.51 | 2024-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $106.38 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $71.84 | 2025 | Ozempic, Wegovy |
| Ardelyx, INC. | $47.70 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $36.59 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $33.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.99 | 2025 | Livtencity |
| Pfizer INC. | $24.90 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.59 | 2023 | Onpattro |
| Exact Sciences Corporation | $19.30 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $17.55 | 2024 | Mounjaro |
| Amarin Pharma, INC. | $15.03 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ayuste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.